Overview

Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Changes in the communication of glutamate from one brain structure to another are important in the development of therapy for cocaine use disorders. Our preliminary investigations suggest that drugs that affect glutamate exchange may be effective at promoting and maintaining individuals' abstinence from cocaine. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cocaine use disorders.
Phase:
Phase 3
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Cocaine
Ketamine